Literature DB >> 22209633

The role of imaging for the surgeon in primary malignant bone tumors of the chest wall.

M Rocca1, M Salone, S Galletti, A Balladelli, D Vanel, A Briccoli.   

Abstract

Primary malignant chest wall tumors are rare. The most frequent primary malignant tumor of the chest wall is chondrosarcoma, less common are primary bone tumors belonging to the Ewing Family Bone Tumors (EFBT), or even rarer are osteosarcomas. They represent a challenging clinical entities for surgeons as the treatment of choice for these neoplasms is surgical resection, excluding EFBT which are normally treated by a multidisciplinary approach. Positive margins after surgical procedure are the principal risk factor of local recurrence, therefore to perform adequate surgery a correct preoperative staging is mandatory. Imaging techniques are used for diagnosis, to determine anatomic site and extension, to perform a guided biopsy, for local and general staging, to evaluate chemotherapy response, to detect the presence of a recurrence. This article will focus on the role of imaging in guiding this often difficult surgery and the different technical possibilities adopted in our department to restore the mechanics of the thoracic cage after wide resections.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Bone tumors; Chest wall; Chondrosarcoma; Ewing sarcoma; Osteosarcoma; Staging

Mesh:

Year:  2011        PMID: 22209633     DOI: 10.1016/j.ejrad.2011.11.029

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  2 in total

1.  Multidisciplinary Assessment of Planning and Resection of Complex Bone Tumor Using Patient-Specific 3D Model.

Authors:  Anil Murat Ozturk; Suzan Sirinturk; Levent Kucuk; Fulya Yaprak; Figen Govsa; Mehmet Asim Ozer; Ufuk Cagirici; Dundar Sabah
Journal:  Indian J Surg Oncol       Date:  2018-12-05

2.  Histological, epidemiological and anatomical analysis of 193 bone tumours of the scapula.

Authors:  Matthias H Priemel; Johannes M E Erler; Jozef Zustin; Andreas M Luebke; Norbert Stiel; Alexander S Spiro
Journal:  J Bone Oncol       Date:  2019-08-22       Impact factor: 4.072

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.